Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas
NCT06669013
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Bone Sarcoma
Embryonal Rhabdomyosarcoma
Alveolar Rhabdomyosarcoma
Interventions
DRUG:
dinutuximab beta
Sponsor
N.N. Petrov National Medical Research Center of Oncology